Ligand's Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of Voyage Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

Ligand Pharmaceuticals Incorporated announced that its partner Viking Therapeutics, Inc. announced positive top-line results from its Phase 2b clinical trial of VOYAGE, a novel liver-selective thyroid... | May 17, 2023

Related Keywords

,Ligand Pharmaceuticals Incorporated ,Therapeutics Inc ,Viking Therapeutics ,Primary Endpoint ,Liver Fat Content ,Nc Stock Exchange ,News ,Information ,Press Release ,Migand ,Pharmaceuticals ,Ncorporated ,Nnounced ,Hat ,Its ,Partner ,Viking ,Positive ,Results ,Rom ,Hase ,Tb ,Linical ,Trial ,F ,Ovel Vktx Us92686j1060 ,